Skip to main content
Be The Investor
S&P 500
7,592.40-0.35%
After Hours7,593.15+0.01%
Nasdaq Composite
25,366.09-0.39%
After Hours25,323.20-0.17%
Dow Jones
52,297.09-0.36%
After Hours52,337.02+0.08%
Russell 2000
2,799.06-1.66%
After Hours2,799.56+0.02%
VIX
VIX
18.70+6.92%
Bitcoin
68,417.33-4.14%
Ethereum
1,915.12-5.07%
Solana
78.57-3.78%
Gold
3,922.90+0.97%
Silver
50.30+0.46%
Copper
6.182-0.08%
WTI Crude Oil
88.30-0.45%
US 10-Year Treasury Yield
5.104+2.12%
Home›Stocks›REPL
OverviewChartNewsFinancialsBusiness ModelCompetitorsStatisticsAnalysisEarningsValuationHoldersOptionsInsidersForecastCompareFAQ

Replimune Group, Inc.

REPL
NASDAQUnited States flagUSReal-Time Price
$21.98USD
+0.20 (+0.92%)Today
$23.35+1.37 (+6.23%)After HoursLast quote · Nov 10, 2026, 6:49 PM ET · Updates paused

Investors Sentoments

Sign in to share your view.

BTI Score

BASIC required or higher

View pricing
BTI Fair Market Cap
$225.26M
+825.04% vs fair
High Risk

Replimune Group, Inc. (REPL) Stock News

The latest Replimune Group, Inc. (REPL) news in one feed: earnings updates, analyst ratings, product launches and regulatory filings, curated and summarized by BTI.

Replimune's TUDRIQEV Launch Shows Early Reach, Not Yet Sales

More than 15 institutions prescribed Replimune's TUDRIQEV during its first weeks on the market. Early access is encouraging, but revenue, repeat use and a required confirmatory trial still determine the launch's value.

Etsy, Replimune and Genmab Hit New Highs on Unequal Catalysts

Etsy showed a measurable marketplace recovery, Replimune disclosed early launch adoption, and Genmab reported pivotal survival data. The three rallies rest on very different levels of evidence.